Contemporary Prospects of Prevention of Type 2 Diabetes Mellitus
Authors:
M. Zeman 1; A. Žák 1,2
Authors‘ workplace:
IV. interní klinika 1. LF UK a VFN, Praha
1; Ústav klinické biochemie a laboratorní diagnostiky 1. LF UK, Praha
2
Published in:
Čas. Lék. čes. 2005; 144: 147-151
Category:
Review Article
Overview
Prevalence of the Type 2 diabetes mellitus (DM2) has been rising in the whole word. It is assumed that before DM2 develops, patients undergo a stadium of impaired glucose tolerance (IGT) or they have impaired fasting glycaemia (IFG). The confirmed IFG or IGT represent strong predictors of DM2 manifestation and at the same time they are related with high cardiovascular risk, namely with IGT. Other significant risk factor (RF) of DM2 is the obesity and metabolic syndrome. Recent clinical studies have shown that some metabolic abnormalities, which precede development of DM2 can be positively influenced by the lifestyle changes, including improvement of the diet and increasing the physical activity. Such measures can prevent or at least to delay the development of type 2 diabetes mellitus and thus the development of cardiovascular diseases. Positive effect has also the administration of some drugs, already tested in clinical studies, namely glitasons, metromin, inhibitor of ACE, sartans and other.
Key words:
type 2 diabetes mellitus, impaired glucose tolerance, metabolic syndrome, obesity, lifestyle changes, diabetes prevention.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistArticle was published in
Journal of Czech Physicians
Most read in this issue
- Foetal ECG in the Prediction of Intrapartum Hypoxia
- Psychosomatics is „Expensive“
- Conservative Therapy of Female Urinary Incontinence – Potential and Effect
- Promise of Immunotherapy of the Chronic Myeloid Leukaemia